Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesEfficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease
The American Journal of Cardiology, 11/24/08
Conard SE et al. – Addition of ezetimibe 10 mg to atorvastatin 20 mg is generally well tolerated with significantly greater lipid-lowering efficacy compared with doubling atorvastatin to 40 mg in hypercholesterolemia pts at moderately high risk for coronary heart disease.
Methods- Study of efficacy and safety of ezetimibe 10 mg added to atorvastatin 20 mg compared with doubling atorvastatin to 40 mg in hypercholesterolemia pts at moderately high risk for coronary heart disease who did not reach low-density lipoprotein (LDL) cholesterol levels <100 mg/dl with atorvastatin 20 mg
- Double-blind, randomized, parallel-group, multicenter 6-wk trial of 196 pts treated with atorvastatin 20 mg
- Administration of atorvastatin 20 mg plus ezetimibe 10 mg or atorvastatin 40 mg for 6 wks
- Significantly greater reductions in LDL cholesterol with ezetimibe plus atorvastatin vs increased atorvastatin (-31% vs -11%)
- Significantly greater reductions in non-high-density lipoprotein cholesterol, total cholesterol, and apolipoprotein B with ezetimibe plus atorvastatin
- Significantly more pts reached LDL cholesterol levels <100 mg/dL with ezetimibe plus atorvastatin vs increased atorvastatin (84% vs 49%)
- Comparable results between treatment groups for high-density lipoprotein cholesterol, triglycerides, apolipoprotein A-I, and high-sensitivity C-reactive protein
- Incidences of clinical and laboratory adverse experiences generally similar between groups
Related Articles
Risk factors for development of coronary artery disease in women with systemic lupus erythematosus
Journal of Rheumatology, 10/20/09
Relevance Score: 90%
Variant metabolic risk factor profile leading to premature coronary disease: time to define the syndrome of accelerated atherocoronary metabolic syndrome in Asian Indians
Singapore Medical Journal, 11/11/09
Relevance Score: 89%
Suppressive effect of EPA on the incidence of coronary events in hypercholesterolemia with impaired glucose metabolism: Sub-analysis of the Japan EPA Lipid Intervention Study (JELIS)
Atherosclerosis, 10/14/09
Relevance Score: 89%
Prognostic value of plasma high-sensitivity C-reactive protein levels in Japanese patients with stable coronary artery disease: The Japan NCVC-Collaborative Inflammation Cohort (JNIC) Study
Atherosclerosis, 11/12/09
Relevance Score: 87%
Risk and prognostic factors for non-specific musculoskeletal pain: A synthesis of evidence from systematic reviews classified into ICF dimensions
Pain, 10/06/09
Relevance Score: 84%
Today in Atherosclerosis/Lipids...keeping you current
Receive free subspecialty "5-minute updates" via email
Functional foods for dyslipidaemia and cardiovascular risk prevention
Nutrition Research Reviews, 12/15/09
Optimizing Vascular Risk Reduction in the Stroke Patient with Atherothrombotic Disease
Medical Principles and Practice, 12/15/09
Impact of progressive resistance training on lipids and lipoproteins in adults: Another look at a meta-analysis using prediction intervals
Preventive Medicine, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor